Calidi Biotherapeutics Inc. Featured for Breakthrough Genetic Medicine Platform
July 8th, 2025 1:59 PM
By: Newsworthy Staff
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been highlighted for its precision genetic medicine platform targeting cancer tumors, offering a novel solution amidst rising global cancer diagnoses.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been featured in a NetworkNewsWire editorial for its innovative precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With the global cancer diagnoses expected to soar to 35 million annually by 2050, Calidi's technology presents a promising avenue for addressing significant unmet needs in oncology. The platform's ability to deliver potent genetic therapies directly to cancer sites could revolutionize cancer treatment, providing a potentially disruptive solution in the ongoing battle against the disease. For more details, visit https://ibn.fm/GZS7L.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
